Veracyte, Inc. (VCYT)

Last Closing Price: 26.96 (2025-05-29)

Company Description

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $445.76M
Net Income (Most Recent Fiscal Year) $24.14M
PE Ratio (Current Year Earnings Estimate) 33.37
PE Ratio (Trailing 12 Months) 29.63
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 4.56
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.77
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 26.00
Pre-Tax Margin (Trailing 12 Months) 7.57%
Net Margin (Trailing 12 Months) 7.13%
Return on Equity (Trailing 12 Months) 6.14%
Return on Assets (Trailing 12 Months) 5.60%
Current Ratio (Most Recent Fiscal Quarter) 5.10
Quick Ratio (Most Recent Fiscal Quarter) 4.78
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) 6.92
Book Value per Share (Most Recent Fiscal Quarter) $15.26
Earnings per Share (Most Recent Fiscal Quarter) $0.18
Earnings per Share (Most Recent Fiscal Year) $0.73
Diluted Earnings per Share (Trailing 12 Months) $0.41
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 78.32M
Free Float 77.22M
Market Capitalization $2.11B
Average Volume (Last 20 Days) 1.07M
Beta (Past 60 Months) 2.14
Percentage Held By Insiders (Latest Annual Proxy Report) 1.40%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%